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Abstract
Where causal SNPs (single nucleotide polymorphisms) tend to accumulate within bio-
logical pathways, the incorporation of prior pathways information into a statistical model is
expected to increase the power to detect true associations in a genetic association study. Most
existing pathways-based methods rely on marginal SNP statistics and do not fully exploit the
dependence patterns among SNPs within pathways. We use a sparse regression model, with
SNPs grouped into pathways, to identify causal pathways associated with a quantitative trait.
Notable features of our pathways group lasso with adaptive weights (P-GLAW) algorithm in-
clude the incorporation of all pathways in a single regression model, an adaptive pathway
weighting procedure that accounts for factors biasing pathway selection, and the use of a
bootstrap sampling procedure for the ranking of important pathways. P-GLAW takes ac-
count of the presence of overlapping pathways and uses a novel combination of techniques to
optimise model estimation, making it fast to run, even on whole genome datasets. In a com-
parison study with an alternative pathways method based on univariate SNP statistics, our
method demonstrates high sensitivity and specificity for the detection of important pathways,
showing the greatest relative gains in performance where marginal SNP effect sizes are small.
1 Introduction
The mixed success of attempts to identify genetic variants that account for a large part of the
heritability of common disease has focussed attention on the need to develop new methodological
approaches to the analysis of GWAS data. A number of factors that might explain this ‘missing
heritability’ have been suggested, including the failure of many current models to capture the
presence of gene-gene and gene-environment interactions, of multiple SNPs with small effect and
of rare variants (Manolio et al., 2009; Goldstein, 2009). One promising approach uses prior in-
formation on functional structure present within the genome to group genes and associated SNPs
into gene sets or pathways. The motivation here is that genes do not work in isolation, but instead
work together through their effect on molecular networks and cellular pathways. The hope is that
by jointly considering the effects of multiple SNPs or genes within a biological pathway, significant
associations might be identified that would otherwise be missed when considering markers indi-
vidually (Wang et al., 2010). First developed in the context of gene expression studies (Mootha
et al., 2003), pathways-based methods have more recently been extended to the analysis of GWAS
data (Holmans et al., 2009; Luo et al., 2010; Lango Allen et al., 2010; Lambert et al., 2010). This
has led to the identification of putative causal pathways for a number of diseases including Parkin-
son’s Disease (Lesnick et al., 2007), Crohn’s Disease (Wang et al., 2009b) and rheumatoid arthritis
(Eleftherohorinou et al., 2011). As well as offering the potential for increased statistical power,
pathways-based genetic association studies (PGAS) can aid the biological interpretation of results
through the identification of causal pathways, and may also facilitate comparisons between studies
genotyping different variants that nonetheless map to common pathways (Ma and Kosorok, 2010;
Cantor et al., 2010).
The majority of existing PGAS methods begin with a univariate test of association, in which
individual SNPs are scored according to their degree of association with disease status or a quan-
titative trait. Various techniques are then used to combine these univariate statistics into pathway
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scores. For example, the GenGen method (Wang et al., 2007) first ranks all genes according to
the value of the highest-scoring SNP within 500kb of each gene. Pathway significance is then
assessed by determining the degree to which high-ranking genes are over-represented in a given
gene set, in comparison with the genomic background. The PLINK tookit (Purcell et al., 2007)
also features a ‘set-based test’, in which pathway significance is measured by taking the average,
marginal p-value of a pre-determined maximum number of ‘uncorrelated’ SNPs within the path-
way. Here, uncorrelated SNPs are defined as those whose pairwise linkage disequilibrium (LD) is
below a certain threshold value. As a final step, where more than one pathway is considered a
correction for multiple testing is generally made.
In contrast to univariate, ‘one SNP at a time’ methods, multivariate or multi-locus methods
allow all SNPs to be considered in the model at the same time, which can aid the identification of
weak signals while diminishing the importance of false ones. One such approach consists of fitting
a penalised, multivariate regression model, in which a subset of SNPs is selected by imposing
a penalty on some suitably selected norm of the regression coefficients, as in Lasso regression
(Tibshirani, 1996). This approach has been shown to yield higher statistical power, compared to
more common ‘mass univariate linear models’, especially with multivariate and high-dimensional
quantitative traits (Vounou et al., 2010). Several other studies have demonstrated the advantages
of this approach for the detection of genetic associations. For example, Wu et al. (2009) use
penalized logistic regression to select SNPs in a case-control study, and analyse two-way and
higher-order SNP-SNP interactions. Hoggart et al. (2008) propose a similar method for SNP
selection in a Bayesian context.
A number of penalized regression techniques that allow prior information on the relationship
between SNP markers to be incorporated into the model selection process have recently been
proposed. For example, Zhou et al. (2010) group SNPs into genes, and utilise a useful property
of the group lasso (Yuan and Lin, 2006) to aid the detection of rare variants within genes. The
GRASS method (Chen et al., 2010) begins by characterising within-gene variation as ‘eigenSNPs’,
obtained by principal component analysis (PCA). A combination of lasso and ridge regression,
followed by permutations is then used to measure significance for a single pathway. Finally, Zhao
et al. (2011) use a combination of PCA and lasso regression to identify a subset of genes within
a candidate pathway, followed by permutations to measure pathway significance. Once again this
method considers one pathway at a time.
The search for SNPs, or quantitative trait loci (QTL) influencing quantitative traits is gaining
momentum as a potentially more powerful way to study the underlying causes of complex disease
(Plomin et al., 2009). In the emerging field of neuroimaging genetics for example, in which we
have a particular interest, quantitative data in the form of MRI or PET scans serve as a type of
intermediate phenotype in the study of complex disorders such as Alzheimer’s Disease (AD) or
schizophrenia (Bigos and Weinberger, 2010). We use genotype data from the Alzheimers Disease
Neuroimaging Initiative (ADNI) dataset in this analysis.
Our focus here is on the identification of biological pathways associated with a quantitative
trait. Our assumption is that where causal SNPs are enriched in a pathway, the use of a regression
model that selects SNPs that are grouped into pathways will have increased power, compared to
a more traditional approach in which SNPs are considered one at a time. We also seek a true,
multivariate model which includes all mapped pathways at the same time. The hope is that this
will confer some of the benefits, in terms of detecting weaker signals and diminishing false positives,
described earlier. To achieve these ends, we use a modified version of the group lasso (GL) with
SNPs grouped into pathways, and develop a fast estimation algorithm applicable to the case of
non-orthogonal groups. In order to rank pathways, we use a bootstrap sampling procedure to rank
pathways in decreasing order of importance. We face a number of challenges in applying GL to
SNP and pathway data for the identification of implicated pathways. These include the fact that
pathways overlap, since many SNPs map to multiple pathways; the problem of selection bias, that
is the tendency of the model to select pathways having specific statistical properties irrespective of
their association with phenotype; and the sheer scale of SNP datasets, making efficient estimation
a necessity.
We have found that the issue of overlapping pathways receives surprisingly little attention in
the PGAS literature, given that the presence of overlaps might be expected to have a significant
impact on the results of any PGAS analysis. For example, variation in the number and distribution
of causal SNPs with respect to genes that overlap multiple pathways will affect the number of
pathways defined to be ‘causal’, and different PGAS methods will be affected by such variation in
different ways. Additionally, the inclusion of multiple pathways in a single GL regression model
presents a particular problem, since GL in its original formulation will not select pathways in
the manner that we would wish. To account for this we employ a variable expansion procedure,
originally proposed in the context of microarray data analysis by Jacob et al. (2009), that ensures
that overlapping SNPs enter the regression model separately, for each pathway that they map to.
A number of factors may bias PGAS results, exaggerating pathway significance and giving
rise to inflated numbers of false positives. Depending on the methods used, and the underlying
disease-causing mechanism, such factors are likely to include pathway size (measured in number of
SNPs and/or genes), and the extent and distribution of pathway LD. Common strategies employed
by existing methods to reduce this bias include the use of permutation (of genes or phenotypes),
and dimensionality reduction techniques such as PCA (Fridley and Biernacka, 2011; Wang et al.,
2010). We propose a procedure that reduces bias by adjusting pathway weightings in the regression
model according to the empirical bias in pathway selection frequencies obtained by fitting the GL
model with a null response.
One potential drawback of using a regression model in the analysis of genetic data is the
typically very large number of predictors (here SNPs) that must be analysed. While the use of
penalized regression techniques at least makes the problem tractable when the number of predic-
tors vastly exceeds sample size, the very large matrix calculations required can still make model
estimation computationally infeasible. To address this, we combine a number of techniques that
speed up the estimation process including the use of an ‘active set’ of predictors, a Taylor ap-
proximation of the GL penalty and efficient computation of pathway block residuals. The final
estimation algorithm, which we call ‘Pathways Group Lasso with Adaptive Weights’ (P-GLAW),
is sufficiently fast to obviate the need either to undertake a preliminary stage of dimensionality
reduction, or to consider pathways individually.
We evaluate our method’s performance in a Monte Carlo (MC) simulation study, using real
genetic and pathway data with quantitative phenotypes simulated under an additive genetic model.
We consider a range of scenarios with different causal SNP distributions and effect sizes. We feel
the use of real genotype and pathway data is crucial, so as to capture the complex distributions
of gene size and number within a pathway, together with SNP LD patterns and overlaps between
pathways, all of which may have a significant effect on pathway ranking performance. To our
knowledge, this is the first such PGAS power study using GL with real SNP and pathway data.
The evaluation of GL pathway ranking performance however presents a number of challenges.
Firstly, as described above, variation in the number of causal pathways due to overlaps must be
taken into account when evaluating performance over multiple MC simulations. Secondly, we
require a means of evaluating the degree to which causal pathways are represented amongst the
top ranks. Thirdly, since GL performs variable selection, not all causal pathways may be ranked,
and ranking performance measures must reflect this. To address these issues we devise a battery
of measures that aim to capture different aspects of ranking performance. Finally, we compare
our method’s performance with another common PGAS method, derived from univariate SNP
statistics.
The article is organised as follows. Section 2 describes the GL model; our strategy for dealing
with overlapping pathways, model estimation and speed-ups; our proposed bias-adjusted pathway
weighting update procedure; our strategy for ranking pathways using a resampling procedure, and
our proposed ranking performance measures. In Section 3 we describe the real biological data sets
used in the experiments, the SNP to pathway mapping process, and the simulation framework
used to evaluate both methods under consideration. The results from these simulation studies are
provided in Section 4, and we conclude in Section 5 with a discussion and final remarks.
2 Methods
2.1 The group lasso for pathway selection
We assume N unrelated individuals genotyped at P SNPs, each with a univariate quantitative
trait yi, for i = 1, . . . , N . For an individual i, we denote by xij the minor allele count for SNP j, for
j = 1, . . . , P , and arrange these counts in an (N × P ) design matrix X. Quantitative phenotypes
are arranged in an (N × 1) column vector y, and will be treated as quantitative responses in a
regression model.
We initially consider the situation where SNPs are partitioned into L mutually exclusive path-
ways, or groups. Each group Gl, for l = 1, . . . , L, is a subset of {1, 2, . . . , P} of cardinality Sl,
containing the indices l1, l2, . . . , lSl of the SNPs that belong to it, such that Gl ∩ Gl′ = ∅ for any
l 6= l′. We denote by G = {1, . . . , P}, the set of all SNP indices. We denote by S ⊂ {1, . . . , P}
the subset of SNPs that are causal, that is the SNPs influencing y, and additionally denote the
cardinality of S by S. Accordingly, we denote by C ⊂ {1, 2, . . . , L} the subset of causal pathways
containing one or more SNPs in S, having cardinality |C|. We denote the complement of C by C′.
We also assume that |C|  L, so that only a small proportion of all pathways are causal. Finally,
we assume that y can be optimally predicted, in the least squares sense, by a linear combination
of allele counts corresponding to SNPs in pathway Gl, where l belongs to the set C.
We denote the vector of SNP regression coefficients β = (β1, . . . , βP ) ∈ RP , and the parameter
vector corresponding to SNPs in pathway Gl only as βl = (βl1 , . . . , βlSl ) ∈ RSl . Under these
assumptions, one or more elements of each βl for l ∈ C are expected to be non-zero, whereas all
the regression coefficients associated with SNPs that do not belong to C will be zero, that is βl = 0
for l ∈ C′. For example, for a single causal pathway Gl with causal SNPs {a, b} in S, the sparsity
pattern might look like
β = {(0, . . . , 0)︸ ︷︷ ︸
G1
, . . . , (0, . . . , βla , 0 . . . , βlb , 0, . . . , 0)︸ ︷︷ ︸
Gl
, . . . , (0, . . . , 0)︸ ︷︷ ︸
GL
}.
A suitable regression model that would enforce the assumed block sparsity pattern above is
the group lasso (GL) (Yuan and Lin, 2006), in which estimates for β are obtained by minimising
the penalised least squares function
(1) f(β) =
1
2
||y −Xβ||22 + λ
L∑
l=1
wl||βl||2
with respect to β, where || · ||2 denotes the `2 (Euclidean) norm and wl is a pathway weighting
factor for group l. Sparsity at the pathway level is encouraged through the imposition of an `1
lasso penalty on ||βl||2, which ensures that SNPs belonging to pathways not selected by the model
have zero regression coefficients. For selected pathways, i.e. those with βl 6= 0, SNP coefficients
tend to shrink, through the imposition of a ridge-type penalty on ||βl||2. The degree of sparsity is
controlled by the regularisation parameter, λ, such that the number of pathways selected by the
model increases with decreasing λ. For a given λ, the block sparsity pattern is determined both
by the data (y and X), and by the distribution of pathway weights, w = (w1, . . . , wl), such that
an increase in wl means that pathway l is less likely to be selected, whereas a decrease in wl will
have the opposite effect.
The GL optimisation problem associated with minimising the objective function (1) is convex,
and can be solved using coordinate descent methods. Problems arise however in the situation
where pathways overlap, that is when a SNP is allowed to belong to more than one pathway, so
that Gl ∩ Gl′ 6= ∅ for some l 6= l′. Firstly, where groups overlap, the penalty term in (1) is no
longer separable into groups, since the same SNPs occur in multiple pathways, and convergence
using coordinate descent is no longer guaranteed (Tseng and Yun, 2009). Secondly, if we wish
to be able to select pathways independently, GL is unable to do this. We illustrate this last
point using a simple example in Fig. 1 A, where we consider only three pathways, G1,G2 and
G3, two of which overlap. As a consequence of this, pathway parameter vectors β1 and β2 also
overlap, since they have a number of SNPs in common (shaded dark grey). If a shared SNP is
selected (i.e. it has a non-zero coefficient), then both pathways to which it belongs (G1 and G2)
are also selected, since their corresponding pathway parameter vectors have non-zero `2 norms.
The GL regression model thus does not meet our requirements, since in order to be able to rank
pathways in order of importance, we wish to be able to distinguish overlapping pathways and
select them independently. Conversely, where shared SNPs have zero coefficients, for example in
the case that G1 is not selected in the model, then these SNPs will have zero coefficients in each
and every pathway to which they belong (here G1 and G2). Hence SNPs retained in the model are
necessarily drawn from the complement of a union of (unselected) pathways. We instead require
retained SNPs to be drawn from a union of (selected) pathways, so that a SNP driving selection
in one pathway may still have a zero coefficient in another.
Figure 1: The problem of overlapping pathways: here there are three pathways, G1,G2 and G3, two of
which overlap. A: Standard formulation. Pathway parameter vectors β1 and β2 overlap, since they have
SNPs in common (shaded dark grey). Where an overlapping SNP has a non-zero coefficient, only G3, can
be selected independently. B: Formulation with duplicated SNPs. An expanded parameter vector, β∗,
is created by duplicating overlapping SNPs (dotted line). β∗1 and β
∗
2 now enter the model separately, so
that pathways can be selected independently.
Jacob et al. (2009) propose one possible solution to the problem of overlapping predictors in a
similar context, motivated by the analysis of gene expression data. The essence of this method is to
create duplicate, dummy SNPs, so that SNPs belonging to more than one pathway enter the model
separately (see Fig. 1 B). The process works as follows. An expanded design matrix is formed from
the column-wise concatenation of the L sub-matrices of size (N × Sl), that is XGl = {xij} with
i = 1, . . . , N and j ∈ Gl, to form the expanded design matrix X∗ = [XG1 ,XG2 , . . . ,XGL ] of size
(N × P ∗), where P ∗ = ∑l Sl. The corresponding parameter vector, β∗, size (P ∗ × 1), is formed
by joining the L, (Sl×1) pathway parameter vectors, β∗l , so that β∗ = [β∗1T ,β∗2T , . . . ,β∗LT ]T . The
model is then able to perform pathway selection in the way that we require, and the optimisation
(1), with β replaced by β∗, and X replaced by X∗ becomes block separable, so that it can be
solved by block coordinate descent. In the following sections we assume both β and X have been
expanded, but omit the ∗ superscript for clarity. Finally, we note that where one or more SNPs
in S overlap multiple pathways, the corresponding number, |C|, of causal pathways will increase.
2.2 Parameter estimation
We seek a solution, βˆ, that minimises the GL objective function (1). Where groups or pathways
are disjoint, so that the penalties are separable into groups, a global solution can be obtained using
block coordinate descent (BCD). Coordinate descent algorithms offer a highly efficient means of
solving convex optimisation problems, and work by breaking down the optimisation into a series of
univariate problems, solving the optimisation for each variable (here SNP) in turn, while holding all
the others fixed, until a suitable minimum based on some stopping criterion is reached (Friedman
et al., 2007). Where variables are grouped, as in GL, estimates are obtained for each pathway
parameter vector, βl in turn, while holding constant the current estimates for all other pathway
parameter vectors, βˆm, (m 6= l), and then cycling through each pathway until convergence.
Yuan and Lin (2006) derive a method for solving GL under the assumption that the group
design matrices, XGl are orthogonal, that is X
T
GlXGl = I. This assumption does not hold in our
case, so in the next section we derive a solution for GL in the case of non-orthogonal groups. We
additionally find that GL estimation using BCD can be slow, particularly for the large datasets
common to PGAS, and so in the following sections propose a number of strategies for speeding
up parameter estimation.
2.2.1 Block coordinate descent for non-orthogonal groups
We assume that (1) is block-separable, that is the groups indexed by 1, . . . , L are disjoint by
construction. In our context, this is achieved by implementing the SNP duplication strategy of
section 2.1. We begin by considering a single pathway l. We collect the N individual observed
SNPs for a given SNP j in a column vector Xj = (x1j , x2j , . . . , xNj). Using this notation, we
define the matrix XGl = (Xl1 , Xl2 , . . . , XSl) containing all Sl SNPs belonging to pathway Gl, and
the corresponding vector of regression coefficients βl = (βl1 , βl2 , . . . , βSl). We can then rewrite the
objective function (1) for a single block l as a function of βl,
(2) f(βl) =
1
2
||rˆl −
∑
j∈Gl
Xjβj ||22 + λwl||βl||2
where rˆl = y −
∑
m6=l Xmβˆm. The vector rˆl is the ‘partial residual’ vector for pathway l, based
on the current estimates, βˆm,m 6= l, of the other pathway parameter vectors.
Estimates for each βj are then obtained by taking partial derivatives with respect to βj , that
is by setting
(3)
∂f(βl)
∂βj
= 0 for j = l1, . . . , Sl
Ignoring the penalty term, the partial derivative with respect to βj is
∂
∂βj
1
2
||rˆl −
∑
j
Xjβj ||22 = −XTj (rˆl −
∑
j
Xjβj)
We denote the partial derivative of the penalty term, by
sj =
∂
∂βj
||βl||2
so that (3) can be written as
(4) −XTj (rˆl −
∑
j
Xjβj) + λwlsj = 0 j = l1, . . . , Sl
We first consider the case where βl = 0, that is βj = 0, for j = l1, . . . , Sl. In this case ||βl||2
is not differentiable. We instead form the Sl sub-differentials, sj ∈ [−1, 1], so that
(5)
∑
j
s2j ≤ 1
The system of equations (4) can now be written
sj =
1
λwl
XTj rˆl j = l1, . . . , Sl
and using (5), we have
(6)
∑
j
s2j =
1
λ2w2l
∑
j
(XTj rˆl)
2 ≤ 1.
Note that for (6) to be unbiased with respect to group size, a weight, wl =
√
Sl, as proposed by
Yuan and Lin (2006), can be applied. Alternatively, since∑
j
(XTj rˆl)
2 = ||XTl rˆl||22
we may rewrite (6) as
(
∑
j
s2j )
1
2 =
1
λwl
||XTl rˆl||2 ≤ 1,
so that if βl = 0
(7) ||XTl rˆl||2 ≤ λwl.
When βl 6= 0, the minimisation of (2) can be obtained numerically, using coordinate descent,
as a series of one-dimensional estimations over βj , j = l1, . . . , lSl . Friedman et al. (2010) suggest
a golden section search over βj , combined with parabolic interpolation. However, the number of
such estimations depends on L and P ∗, both of which increase with P , the latter markedly so.
This can make the GL optimisation prohibitively slow, particularly for the large P typically found
in PGAS. For this reason, we next describe three strategies for speeding up the estimation.
2.2.2 Taylor approximation of penalty
One means of speeding up the estimation for βj is to use a linear or quadratic approximation of the
GL `2 penalty (Zou and Li, 2008; Fan and Li, 2001), enabling the replacement of the multi-step
numerical optimisation over βj with a one-step calculation. Breheny and Huang (2009) propose the
use of a Taylor approximation for a range of different estimation problems with grouped variables
and we adopt this approach for our GL estimation problem. We begin by rewriting the group Gl
objective function (2), for a single predictor as
f(βl|βˆk, k ∈ Gl, k 6= j) = 1
2
||rˆl −
∑
k
Xkβˆk −Xjβj ||22 + λwlΓ(βl|βˆk)
where Γ(βl|βˆk) = (c + β2j )
1
2 , with c =
∑
k 6=j βˆ
2
k, and the βˆk are the current SNP coefficient
estimates. For convenience, we rewrite this as
(8) f(βl|βˆk, k 6= j) = 1
2
||rˆ +Xj βˆj −Xjβj ||22 + λwlΓ(βl|βˆk)
where rˆ = y −∑l Xlβˆl is the total residual, using the current estimates of all SNP coefficients.
We now consider the first order Taylor expansion of Γ(βl|βˆk) as a function of x = β2j , about the
point a = βˆ2j
Γ(x) ' Γ(a) + Γ′(a)(x− a)
Now
Γ(x) = (c+ x)
1
2
and Γ′(a) =
1
2(c+ a)
1
2
so that
Γ(x) ' (c+ a) 12 + x− a
2(c+ a)
1
2
Substituting a = βˆ2j , and noting that (c+ a)
1
2 = ||βˆl||2, where βˆl denotes the current estimate of
βl, this gives
Γ(β2j ) ' βˆl +
β2j − βˆ2j
2||βˆl||2
Substituting this expression in (8), we have
f(βl|βˆk, k 6= j) = 1
2
||rˆ +Xj βˆj −Xjβj ||22 + λwl
[
βˆl +
β2j − βˆ2j
2||βˆl||2
]
Differentiating with respect to βj gives
∂f(βl)
∂βj
∣∣∣∣
βˆk,k 6=j
= −XTj (rˆ +Xj βˆj −Xjβj) + λwl
βj
||βˆl||2
= −XTj rˆ− βˆj + βj + λwl
βj
||βˆl||2
since
∑
i x
2
ij = X
T
j Xj = 1. Rearranging terms and setting the partial derivative equal to zero, we
see that the minimum is achieved when
(9) βj =
XTj rˆ + βˆj
1 + λ′
where λ′ =
λwl
||βˆl||2
Where the current estimate ||βˆl||2 = 0, that is when group l first enters the estimation, we set
||βˆl||2 to be a small positive quantity, η, enabling βj in (9) to be estimated.
BCD proceeds by obtaining estimates for each βj , j = l1, . . . , Sl, 1, . . . , Sl, . . . until convergence
within the block, and for each pathway, l = 1, . . . , L, 1, . . . , L, . . . in turn, until a stopping criterion
indicating a global minimum of (1) has been satisfied. The estimation process is summarised in
Box 1.
2.2.3 Use of pathway ‘active set’
For large P ∗ and L, the need for the repeated calculation of (7) to establish whether or not
a particular group can enter the estimation presents a major computational bottleneck. This
problem motivates another strategy providing substantial gains in computational efficiency for
a range of sparse regression problems. This ‘active set’ strategy relies on the pre-selection of a
subset of ‘potentially active’ predictors, or groups of predictors that are likely to be selected by
the model at a given λ (Tibshirani et al., 2010; Roth and Fischer, 2008). The optimisation can
then be run over this reduced set of variables, with a subsequent check to ensure that no other
predictors should have been included in the first place. The active set procedure offers potentially
dramatic speed up in execution times, particularly for very large datasets such as those found in
PGAS, due to the reduced number of computations that need to be performed. In addition there
are substantial savings in the amount of memory required to store data during processing, which
Box 1 GL estimation algorithm using BCD
1. set βˆ = 0.
2. For pathway Gl, l = l1, 2, . . . , L:
set rˆl = y −
∑
m6=l Xmβˆm
If ||XTl rˆl||2 ≤ λwl
set βˆl = 0
else
do
for j = l1, . . . , Sl
estimate βj using (9)
end
until convergence of f(βl) (2)
set βˆl = βl
end
end
3. Repeat step 2 until (global) convergence of f(β)(1)
can also lead to dramatic reductions in computation times with large datasets where memory is
constrained.
For the GL, we begin by considering the inequality (7). For groups to enter the model we
require
(10) ||XTl rˆl||2 > λwl l = 1, . . . , L
and therefore, at the first iteration, with β initialised to zero, a group Gl enters the model if
(11) ||XTl y||2 > λwl l = 1, . . . , L.
We define the ‘active set’ A of potentially active groups that satisfy (11) as
A = {m ∈ G : ||XTmy||2 > λwm}
and additionally define
(12) λmax = min
λ
: ||XTl y||2 ≤ λwl l = 1, . . . , L
namely the smallest λ value for which the active set is empty. Note that provided λ is close to
λmax, then |A|  L. Once one or more groups enter the model, not all βˆl will be zero and the
inequality (10) will then determine which groups may enter or leave the model.
The active set procedure rests on the observation that in practice, the final set of groups
selected by the model rarely includes any groups not in A (Tibshirani et al., 2010). We can
therefore perform the full estimation on A, followed by a check of the inequality (10), to see if
any additional groups not in A can enter the model. If there are no additional groups, then we
have the full solution. If not, then we run the full estimation again, with the additional groups
satisfying (10) added to A. A summary of the active set algorithm is given in Box 2.
2.2.4 Efficient computation of block residuals
A further, large computational burden results from the repeated calculation of the residuals rl
and r in (7), (9) and (10). The computational overhead for these calculations is substantial,
both because of the size of the expanded design matrix (N = 743 and P ∗ = 66, 085 in the
Box 2 Active set algorithm for a single λ value
1. Form the active set, A = {m ∈ G : ||XTmy||2 > λwm}
2. Set βˆ = 0, and solve the GL estimation at λ, using only the groups in A:
βˆ = min
β
1
2
||y −
∑
m∈A
Xmβm||22 + λ
∑
m∈A
wm||βm||2
3. Compute the revised active set on the full dataset:
A+ = {z ∈ G : ||XTz rˆz||2 > λwz}
if A+/A = ∅
βˆ is the full solution
STOP
else
set A = A+
repeat 2. and 3. with the new, (expanded) active set
end
simulation study described in section 3, but substantially larger for a full PGWAS), and because
of the iterative nature of the BCD algorithm, meaning that a very large number of calculations are
performed. We therefore achieve one further substantial gain in computational efficiency by noting
that since the blocks are separable, during BCD only the single block residual, hl = y − Xlβl,
changes between iterations j = 1, . . . , Sl, 1, . . . , Sl, . . . within block l, and between iterations l =
1, . . . , L, 1, . . . , L, . . . across blocks. We therefore only need update hl at each iteration, with r and
rl updated using computationally inexpensive matrix subtractions and additions. Python code for
mapping SNPs to pathways, and for analysing SNP data using PGLAW is available on request.
2.3 Selection bias and pathway weighting
PGAS methods derived from univariate SNP statistics are subject to various biasing factors that
can influence pathway ranking under the null, where no SNPs influence the phenotypic trait, y.
These factors vary from method to method, but may include the number and size of genes in a
pathway, as well as LD between SNPs and genes. Such biasing factors are generally corrected
through the use of permutation procedures. For example, the ‘GenGen’ method (Wang et al.,
2009b), measures the degree to which pathways are enriched with high ranking genes, and is sub-
ject to bias due to variation in the number of SNPs mapped to a gene, and to differences in LD
between SNPs mapped to different genes. The bias correction procedure begins by forming multi-
ple datasets through permutation of phenotype labels. For each permuted dataset, gene scores are
generated from univariate SNP statistics, and a pathway enrichment score is calculated. A nor-
malised (bias-corrected) pathway enrichment score is then derived by comparing the distribution
of pathway scores under the null with the score obtained from the unpermuted data.
Regression-based methods are similarly prone to bias, and once again the use of permutation
has been proposed to correct for this, along with dimensionality reduction to extract non-redundant
information. For example, with the GRASS method for case-control data (Chen et al., 2010), ge-
netic information within each gene is first summarised as ‘eigenSNPs’, obtained through PCA. The
biasing effect of gene size is once again accounted for through the generation of a null distribution,
formed by permuting phenotype labels.
With the GL under the null, pathway selection will be influenced by pathway size (i.e. the
number of SNPs within a pathway), since the accumulation of spurious associations in larger
pathways will give rise to larger ||βl||2 in (1). In addition, variation in dependencies between
SNPs within pathways, and to a lesser extent between pathways will give rise to corresponding
variations in ||βl||2 where spurious associations arise in regions of high LD.
One way to correct for biases arising from variations in the statistical properties of different
pathways or groups is through the selection of appropriate group weights w = (w1, . . . , wL) for the
objective function (1). For example, as noted before, Yuan and Lin (2006) suggest one possible
choice for the pathway weighting would be
(13) wl =
√
Sl
which ensures that groups of different size are penalised equally, and so have an equal chance of
being selected by the model, other things being equal (see (6)). In principle, we could follow this
strategy and perhaps attempt to account for other, additional factors that may also bias pathway
selection. However, there are a number of problems with this approach. Consider for example the
biasing effect of dependencies between SNPs within a pathway. Where causal SNPs tag, or reside
within large blocks with strong LD, the pathway ‘signal’ will be high, increasing the chance that
such pathways will be selected by the model, compared with other pathways where LD is low.
This biasing effect will further depend on the distribution of LD within the pathway, which will in
turn depend on other factors such as the number and size of pathway genes. The precise form of
any additional term(s) that should be added to (13) to account for this bias is thus unclear. Even
if we were able to identify a list of potential biasing factors, and formulate bias-correcting weight
adjustments for each, we are still faced with the problem that their may be other, unknown factors
that contribute to the bias. We therefore choose to adopt a ‘hypothesis-free’ approach to adjusting
pathway weights, which makes no assumptions about those factors which might influence pathway
selection.
Consider pathway selection under the GL model (1), with λ tuned to select M pathways.
We begin with the case M = 1. When there is no selection bias, and assuming no genetic
association, a pathway Gl should be randomly selected by the model according to a uniform
distribution, namely with probability Πl = 1/L, for l = 1, . . . , L. However, when biasing factors
are present this is generally not the case, and the empirical probability distribution describing
pathway selection, Π∗(w) will not be uniform. Here the dependence upon the weight vector w
has been made explicit, since with λ tuned to select a single pathway, w alone determines the
frequency distribution. A measure of distance between these two distributions can be obtained by
computing their Kullback-Leibler (KL) divergence
(14) D =
∑
l
Π∗l (w) log
Π∗l (w)
Πl
where Π∗l (w) is the empirical probability for the selection of pathway Gl under the assumption
of no genetic associations. When GL pathway selection is unbiased, we expect this distance to
be approximately zero. Our strategy consists in adaptively adjusting all weights w in order to
minimise D.
Our adaptive weighting procedure is an iterative one, whereby at each iteration τ we first
update the previous weight vector w(τ−1), and then re-estimate Π∗(w(τ)) by fitting the GL model
R times, each with a random permutation of the response in order to create R null data sets2.
Π∗l (w
(τ)) is then the frequency at which pathway Gl is selected across the R null data sets at
iteration τ . The algorithm is initialised at iteration τ = 0 by using an initial weight vector w(0),
for instance the standard size weighting (13). This procedure is then repeated until D reaches
some suitably small value.
From (14), a reduction in D can be obtained by reducing the difference dl = Π
∗
l (w)− Πl, for
all l. As each |dl| approaches zero, the ratio, Π∗l (w)/Πl, approaches one, so that the contribution
of pathway Gl to D is decreased. With this in mind, at each iteration, we adjust pathway weights
according to the following formula,
(15) w
(τ)
l = w
(τ−1)
l
[
1− sign(dl)(α− 1)L2d2l
]
0 < α < 1
2Alternatively, in a simulation study where the null distribution of the response is known (as in section 3), the
R models can be fitted after sampling a response from that null distribution.
where the paramater α controls the maximum amount by which each wl can be reduced in a
single iteration, in the case that pathway Gl is selected with zero frequency. The weighting update
equation has the following desirable properties. When 0 ≤ Π∗l < Πl, i.e. − 1L ≤ dl < 0, wl is
decreased, up to a maximum factor α when Π∗l = 0, increasing the chance that group l is selected.
When Π∗l > Πl, i.e. dl > 0, wl is increased, decreasing the chance that group l is selected. Finally,
when Π∗l = Πl, i.e. dl = 0, wl is unchanged. The square in the weight adjustment factor ensures
that large values of |dl| result in relatively large adjustments to wl.
The estimation of Π∗ when M > 1, that is where more than one pathway is selected by the
model, is computationally infeasible even for a small value of M , since we would need to estimate
the empirical joint probability distribution that M pathways are jointly selected. However, we
expect that many of the factors biasing pathway selection when M = 1 will similarly affect this
joint probability distribution. Under this assumption, we estimate the optimal weight vector w
only in the M = 1 case. Extensive simulation studies (see section 4) indicate that this data-driven
adaptive waiting scheme is able to substantially increase power and specificity compared with the
standard weighting (13), even when M > 1, indicating that this assumption holds in practice.
Finally, we note that despite the need for multiple MC simulations over multiple iterations, our
proposed bias-adjusted weighting strategy is fast, since it relies on fitting the GL model with λ
tuned to select a single pathway only, ensuring that the active set (see section 2.2.3) is very small,
and model estimation time for each of the R model fits is minimal.
2.4 Pathway ranking
Penalized regression typically proceeds by determining an optimal value for λ, corresponding to a
subset of variables that best predicts the response, and this is generally done by cross validating
the prediction error. In genetic association mapping, results are often instead presented in the
form of lists of pathways or SNPs, ranked in order of importance. We seek such a strategy for
the ranking of pathways within the regression model, such that pathways in C, will achieve a
high ranking, whereas those in C′ will be ranked low. This approach has the added advantage of
allowing us to make direct comparisons with alternative pathway methods that use p-values as a
ranking criterion.
One simple ranking criterion in penalised regression is to use the order in which each variable
enters the model along the regularization path - i.e. as λ is decreased from its maximal value, where
no variables are selected. We instead adopt a bootstrap sampling approach, in which we fit the
regression model over multiple subsamples of the data, drawn with replacement, at a single, fixed
value for λ. Pathways are ranked in order of importance according to their selection frequency
across subsamples. Our motivation here is to exploit knowledge of finite sample variability obtained
by subsampling, to achieve better estimates of pathway importance. In this respect our strategy
resembles the pointwise stability selection method proposed by Meinshausen and Bu¨hlmann (2010)
in the context of variable selection.
As with stability selection, for our ranking strategy to be effective, the value of λ must be
small enough to ensure that all pathways in C are selected by the model with a high probability at
each subsample. Computation time increases rapidly with M , the number of selected pathways,
so that with the number, |C|, of causal pathways unknown, the choice of M is driven by the
number of causal pathways we seek to identify within computational constraints. We use B = 100
subsamples, each of size N/2, and at each subsample we perform a line search over λ, to ensure that
M ≥Mmin pathways are selected. This procedure is described in appendix 5. Once λ is tuned, for
each subsample, b, we obtain estimates β
(b)
j (b = 1, . . . , B) for each SNP coefficient (j = 1, . . . , P
∗).
For pathway Gl, we define pi(b)l = 1 when ||β(b)l ||2 6= 0 and pi(b)l = 0 otherwise, where β(b)l is the
pathway parameter vector estimated for subsample b. We rank pathways in order of their selection
frequency across subsamples, p¯il1 ≥, . . . ,≥ p¯ilL . We note that since typically M  L, some p¯il may
be zero. Such pathways are classified as unranked.
2.5 Ranking performance measures
In order to evaluate the success of any PGAS method, some measure of ranking performance
is required. In this section we describe 3 separate ranking performance measures that we use
to evaluate the performance of our method in a simulation study described in section 3. One
complicating factor is the issue of overlapping pathways, making the effective number of causal
pathways, |C|, dependent on the degree to which SNPs in S overlap multiple pathways. In addition,
with any method based on variable selection, the possibility that causal pathways are unranked,
i.e. they are not selected by the model, must be taken into account.
Consider the situation where the set S of causal SNPs, with cardinality S > 1, is known. We
may choose to define C in its most restricted sense as the set of pathways that contain all members
of S, or alternatively C might include all pathways containing one or more SNPs belonging to S.
In either case |C| will depend on the degree to which SNPs in S overlap multiple pathways. This
in turn depends on the particular distribution of causal SNPs with respect to overlapping genes.
The need to accommodate this variability in |C| in part motivates our formulation of the ranking
measures described below.
We propose three separate ranking measures that capture different aspects of ranking perfor-
mance, and focus on the top 100 ranked pathways only. We do this firstly because in any method
attention is inevitably focused on the highest ranking pathways (or alternatively those with the
highest statistical significance in a hypothesis testing framework). Also, since in a simulation study
we compare the performance of our variable selection method which identifies a limited number
of pathways against an alternative method that scores all pathways, some suitable cutoff in rank
order must be chosen.
We denote the set of ranked causal pathways by C∗ = {k ∈ C : p¯ik > 0}, cardinality |C∗|,
and their respective rankings by rk1 , rk2 , . . . , r|C∗|, ranked in order of their respective selection
frequencies, p¯ik1 < p¯ik2 <, . . . , < p¯i|C∗|. We further denote by C∗100 = {k ∈ C∗ : rk ≤ 100},
cardinality |C∗100|, the set of ranked causal pathways falling in the top 100 ranks, with corresponding
rankings rk1 , rk2 , . . . , r|C∗100|. Our three proposed ranking measures are as follows:
1. Highest causal pathway rank, rk1 , that is the single highest rank achieved by any pathway
in C∗100. This lies in the range 1 ≤ rk1 ≤ 100, and is only defined for |C∗100| ≥ 1.
2. Ranking power, p100, defined as
(16) p100 =
|C∗100|
|C|
with 0 ≤ p100 ≤ 1. p100 = 0 when no causal pathways are ranked in the top 100 (C∗100 = ∅),
and p100 = 1 when all causal pathways are ranked in the top 100 (C∗100 = C).
3. Power-adjusted, normalised, weighted ranking score, R. This takes account of the actual
rankings, rk1 , . . . , r|C∗100|, as well as the ranking power, p100. We begin by defining a nor-
malised, weighted ranking score,
(17) R∗ =
∑
k∈C∗100 r
1
2
k∑|C∗100|
k=1 k
1
2
Here the square root increases the weight given to highly-ranked causal pathways. The
denominator is a normalising factor which represents the minimum possible weighted ranking
score, with rk1 = 1, rk2 = 2 . . . , r|C∗100| = |C∗100|, ensuring that R∗ attains its minimum value
of 1 when the pathways in C∗100 are optimally ranked. Higher values of R∗ indicate suboptimal
ranking. R∗ takes no account of the possibility that C∗100 6= C, i.e. not all causal pathways
are ranked. To do this we form the adjusted measure
(18) R =
{
R∗/p100 if p100 > 0
γ if p100 = 0
R thus attains a minimum value of 1 when all causal pathways are optimally ranked, and
the value γ when no causal pathways are ranked.
3 Simulation Study
We assess the power of our proposed method in a simulation study using real genotype and pathway
data, with simulated, quantitative phenotypes generated under an additive genetic model from
SNPs within a single, selected causal pathway. The presence of overlapping SNPs means that
the actual number of causal pathways is typically greater than one. We additionally compare
our method’s performance with an alternative, univariate-based method commonly used in gene
set analysis. Computation times for both methods increase with P , and because of this, and the
large number of scenarios and simulations tested, we restrict this analysis to SNPs on a single
chromosome to keep execution times within practical limits.
3.1 Genotype and pathways data
We use genotypes obtained from the Alzheimer’s Disease Neuroimaging Initiative, ADNI (www.
loni.ucla.edu/ADNI), derived from the Illumina Human 610-Quad BeadChip. Subjects comprise
a mix of healthy controls, those diagnosed as having mild cognitive impairment, and those with
AD. After removing variants with a call rate < 95%, minor allele frequency (MAF) < 0.1 and
significant deviation from Hardy-Weinberg equilibrium (p < 5.7×10−7), 448, 294 SNPs remain. In
this study we use genotype data from N = 743 subjects, and consider only SNPs from chromosome
1 (33, 850 SNPs).
Popular databases used for the mapping of genes to biological pathways include the Kyoto
Encylopedia of Genes and Genomes (KEGG, www.genome.jp/kegg/pathway.html) and BioCarta
(www.biocarta.com/genes/index.asp). For this study we use data on ‘canonical pathways’ from
the Molecular Signals Database (MSigDB, www.broadinstitute.org/gsea/msigdb/index.jsp),
which is a commonly-used, curated collection of pathways obtained from multiple sources. At the
time of writing this comprised 880 pathways mapped to 6, 804 genes. 2,382 human gene locations
on chromosome 1, corresponding to assembly GRCh37.p3 are obtained using Ensembl’s biomart
API (www.biomart.org). ADNI-genotyped SNPs on chromosome 1 are then mapped to annotated
genes within 10kb (20,399 SNPs mapped to 2,096 genes), and these remaining genes and SNPs
are then mapped to pathways using MSigDB (8,102 SNPs mapped to 778 pathways). Thus we
see that the majority of chromosome 1 SNPs fail to map to any pathway, but that the majority
of annotated pathways map to at least 1 SNP on this chromosome. Finally, small (< 10 SNPs)
and identical pathways are removed. After all pre-processing we are left with a total of P = 8, 078
SNPs mapped to 551 pathways (max: 1, 059; min: 10; mean: 120± 142 SNPs per pathway). All
SNP to pathway mapping and filtering was performed using bespoke code written in Python. The
mapping and filtering process is illustrated in Fig. 2.
More than 80% of SNPs are observed to overlap more than 1 pathway, with around 20%
overlapping 10 or more pathways and 2% overlapping 60 or more (see Fig. 3). After variable
expansion to account for overlapping pathways (section 2.1), we have P ∗ = 66, 085 SNPs.
3.2 Simulation framework
We begin by adjusting the pathway weight vector, w, using the bias-adjusted adaptive weighting
procedure described in section 2.3. We do this over 10 iterations with R = 40, 000 MC simulations,
each with response y sampled from a standard normal distribution, N (0, 1) for simplicity, since
many quantitative traits are expected to follow a normal distribution.
For the simulation of a SNP-dependent response, we begin by drawing S SNPs from a single,
randomly selected causal pathway, Gφ, according to some specified distribution (see below), and
then form the set C, of causal pathways that contain all the members of S. We thus chose to
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Figure 2: SNP to pathway mapping.
define C in its most restricted sense, rather than for example including pathways that contain
one or more SNPs in S. Note that the number, |C| of causal pathways will vary according to the
particular distribution of overlaps within S.
For each simulation, a univariate quantitative phenotype y is simulated using an additive
model,
yi =
∑
k∈S
ζkxik + 
where ζk is the allelic effect per minor allele due to causal SNP k. Setting wk = ζkxk, we define
the effect size of SNP k as δk = E(wk)/E(y) for k ∈ S, and set  ∼ N (1, σ2 ) so that δk = 0 when
ζ = 0. We also record the average SNP effect size as a proportion of total phenotypic variance,
ESk = Var(wk)/Var(y), and the mean proportionate change in response per minor allele, E(ζk).
For our simulations we control δk, and set ζk accordingly, so that effect size is independent of SNP
MAF, whereas ζk and ESk are MAF-dependent.
The power and specificity of any PGAS method is likely to depend on a range of factors in-
cluding the number of causal pathways to be identified, the number and distribution of causal
SNPs, and the size of their phenotypic effect (Wang et al., 2010; Fridley and Biernacka, 2011).
We therefore assess the performance of our method across 6 different scenarios in which we vary
each of these factors. Furthermore, we test each scenario over 500 MC simulations to account for
variation in causal SNP MAFs, gene size and number within pathways, and LD patterns within
and between causal pathways.
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Figure 3: Frequency distribution of ADNI SNPs by number of pathways they map to. SNPs are mapped
to genes within 10kbp. The data set consists of 8, 078 SNPs and 551 pathways.
scenario S δk distribution description
(a) 10 0.005 random from Gφ S large; δk large; random distribn
(b) 3 0.005 random from Gφ S small; δk large; random distribn
(c) 3 0.005 random from single gene in Gφ S small; δk large; single gene
(d) 10 0.001 random from Gφ S large; δk small; random distribn
(e) 3 0.001 random from Gφ S small; δk small; random distribn
(f) 3 0.001 random from single gene in Gφ S small; δk small; single gene
Table 1: Scenarios tested in simulation study. For scenarios (c) and (f), in the rare event that a gene has
less than 3 SNPs, all SNPs within the gene are selected.
The list of scenarios tested is presented in Table 1. First, we consider scenarios where the
number of causal SNPs is small (S = 3) or large (S = 10). Secondly, we consider two different
SNP effect sizes. We choose values for σ2 and δk to mimic effect sizes obtained in recent association
studies, focussing particularly on the smallest reported effect sizes. Park et al. (2010) review GWAS
for a number of quantitative traits (height, Crohn’s disease and breast, prostate and colorectal
cancers) and report values for ESk ranging from 0.02 to 0.0004. Cho et al. (2009) report values
for ζk for 8 quantitative traits in a large GWAS ranging from 1.6 to 0.006. A recent neuroimaging
genetic study measuring genetic effects on a variety of traits related to brain structure reports
significant values for ζk of around 0.07 (Joyner et al., 2009). We set σ = 0.2, and test δk = 0.005
and 0.001, which gives values for ESk = 0.001 and 0.00004 and E(ζk) = 0.01 and 0.002 respectively.
Finally, we also vary the particular distribution of SNPs with respect to their location within causal
pathways. We expect the distribution of causal SNPs with respect to genes and associated LD
blocks to affect performance, both in our regression model, and in the case where pathway scores
are derived in a two-step process that begins with the calculation of gene association scores (Wang
et al., 2007). The distributions of |C|, the number of causal pathways for each scenario, are shown
in Fig. 4.
4 Results
We begin with an investigation of the effect of our proposed speed ups to the GL estimation
algorithm. We first note that GL estimation times will depend on the sample size (N) and the
number of SNPs (P ), which will in turn affect the number of mapped pathways (L) and P ∗.
Estimation times will further depend on the number of groups selected (M), and the amount of
signal present, since this affects convergence times. For illustrative purposes, in Table 2 we show
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (a)
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (b)
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (c)
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (d)
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (e)
10 20 30 40 50 600
0.2
0.4
0.6
0.8
1
|C |
fre
qu
en
cy
scenario (f)
Figure 4: Distributions of |C| across 500 MC simulations for the 6 scenarios described in Table 1. Where
SNPs are distributed within a single gene (scenarios (c) and (f)), the number of causal pathways tends to
be larger, since a single gene can map to multiple pathways. Where SNPs are distributed randomly across
Gφ (scenarios (a), (b), (d), and (e)), this number tends to be smaller, particularly where the number of
causal SNPs is large (scenarios (a) and (d)).
gains in execution time compared with ‘standard’ block coordinate descent, using our proposed
speed ups for a single model fit with a null response, and for M = 10. Estimation times are seen to
be substantially reduced across a range of values for N and P , dramatically so for larger datasets.
We next turn to the application of P-GLAW to real genotype and pathway data described in
section 2.3. We apply this procedure over 10 iterations, each with R = 40, 000 MC simulations
with a response y ∼ N (0, 1). Fig. 5 (c) shows how the weight adjustment factor w(τ)/w(τ−1), (see
(15)), varies with dl across all pathways at a single iteration. Fig. 5 (a) and (b) shows the observed,
empirical distribution, Π∗, using the standard size weighting (13), and the adapted weights (15)
after 10 iterations, respectively. The corresponding KL divergence measure, D, is observed to re-
duce steadily over the 10 iterations (Fig. 5 (d)), illustrating how the proposed weight adjustment
procedure reduces pathway selection bias.
For the remainder of this section, we assess the performance of our proposed P-GLAW method
using simulated phenotypes under the simulation framework described in the previous section,
and using the bias-adjusted pathway weights described above. We first compare performance
using the bias-adjusted weights with that obtained using the standard size weighting (13). We
find the adjusted weighting scheme offers a considerable improvement in ranking performance
for all ranking measures, and illustrate this in Fig. 6 for a single scenario (scenario (a)) using
the ranking performance measures described in section 2.4. Fig. 6 (a) shows the first ranking
measure (rk1) as a ROC curve, in which we show the proportion of simulations with rk1 ≤ z,
for ranks z = 1, 2, . . . , 100. We plot z on the horizontal axis as a false positive rate (FPR), so
that FPR = (z − 1)/L. At a FPR of 0.05, we see that the adapted weighting scheme shows a
more than 2 fold increase in power (from 0.29 to 0.62) over the standard pathway size weighting
(13), indicating 62% of MC simulations have rk1 ≤ 28, compared with 29% for the standard size
weighting. The distribution of p100 across 500 MC simulations is illustrated as a boxplot in Fig. 6
(b). Here we see that the adapted weighting scheme offers a clear and substantial improvement in
P ∗ = 4k, L = 126 P ∗ = 66k, L = 551 P ∗ = 647k, L = 879
sample size BCD BCD+ BCD BCD+ BCD BCD+
371 (N/2) 7.93 0.17 421 1.35 5490 16
743 (N) 16.9 0.27 511 2.5 6430 30.0
Table 2: GL estimation times (seconds) with M = 10. Table shows the time taken for the full estimation
with a null N ∼ (0, 1) response, and with varying number of SNPs (P ∗), and sample size (N). ‘BCD’ -
estimation using block coordinate descent only. ‘BCD+’ - estimation using BCD with active set, Taylor
approximation of the group penalty and efficient computation of block residuals. Genotype and pathway
data as described in section 3.1. P ∗ = 4k : 5, 000 SNPs from chromosome 1 mapped to 126 pathways.
P ∗ = 66k : all 33, 850 genotyped SNPs from chromosome 1 mapped to 551 pathways. P ∗ = 647k : 448, 294
genome-wide SNPs mapped to 879 pathways. All computations performed using multi-threading on a
single machine with 8 3.2 GHz processors and 64GB RAM.
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Figure 5: Application of bias-adjusted weighting procedure to the data used in the simulation study.
R = 40, 000, with a different null response, y ∼ N (0, 1), at each MC simulation. α = 0.98. (a) Empirical
pathway selection frequency distribution, Π∗, with standard, pathway size weighting, wl =
√
Sl. D = 2.24.
Dotted horizontal line shows the expected distribution, Πl = 1/L ' 0.002. (b) Π∗ with bias-adjusted
weights after 10 iterations. D = 0.12. (c) Variation of weighting adjustment factor w(τ)/w(τ−1) with dl
at a single iteration, with α = 0.98. Each point represents the adjustment to a single wl, l = 1, . . . , L. (d)
Decrease in K-L divergence, D, over 10 iterations.
GL’s capacity to rank a high proportion of causal pathways in the top 100 (p = 2.03× 10−50 that
the two population p100 CDFs are equal using a two-sample Kolmogorov-Smirnov (KS) test). GL
with the standard weighting scheme performs particularly poorly with 55% of simulations failing to
rank any causal pathway in any simulation, compared with 18% for the adapted weighting scheme.
Finally, Fig. 6 (c) shows the distribution of the R ranking measure across 500 simulations under
the two weighting schemes. Once again we see that the adaptive weighting scheme demonstrates
improved ranking performance over the standard size weighting scheme, with the distribution of
R scores skewed towards lower values for the former, indicating that causal pathways tend to be
ranked higher.
We next assess P-GLAW ranking performance with the adapted weighting scheme across the
full range of scenarios, and compare these with pathway rankings obtained using the method pro-
posed by Wang et al. (2007), commonly referred to as ‘GenGen’ (GG). GG is a widely-used, GSEA-
type PGAS method that measures pathway enrichment using genes scores derived from univariate
SNP statistics. Studies using GG include searches for implicated pathways in Crohn’s disease
(Wang et al., 2009b), autism spectrum disorders (Wang et al., 2009a), breast cancer (Menashe
et al., 2010) and Alzheimer’s disease (Lambert et al., 2010). GG begins by scoring each SNP ac-
cording to its association with the phenotype. SNPs are then mapped to genes within a specified
distance, and each gene is scored according to its most significant mapped SNP. The enrichment
of highly-ranked genes in a given pathway is then compared with those in all other pathways,
to obtain a pathway enrichment score. For GenGen we use identical source data (genotypes,
phenotypes, SNP to gene, and gene to pathway mappings), and rank pathways by normalised
enrichment score, determined from 1,000 permutations (the GG default settings). MC simulations
for P-GLAW and GG are performed in parallel across 50 (P-GLAW) and 500 (GG) processors re-
spectively, on a high-performance computing cluster. As described above for alternative weighting
schemes, results for the comparison study are presented in the form of rk1 ROC curves (Fig. 7),
p100 boxplots (Fig. 8) and R bar graphs (Fig. 9). Selected ranking measures are presented in
numerical form in Tables 3 and 4.
scen. ROC power, fpr = 0.05 median p100 propn. p100 = 0 KS 2 sample test
P-GLAW GG ratio P-GLAW GG ratio P-GLAW GG ratio p100 cdfs the same
(a) 0.62 0.35 1.76 0.60 0.60 1.00 0.18 0.26 0.70 p = 0.0082
(b) 0.61 0.33 1.84 0.33 0.11 3.00 0.21 0.45 0.46 p = 9.6× 10−25
(c) 0.81 0.54 1.49 0.35 0.20 1.73 0.06 0.23 0.25 p = 2.5× 10−25
(d) 0.44 0.18 2.37 0.33 0.00 ∞ 0.30 0.62 0.48 p = 7.7× 10−27
(e) 0.59 0.27 2.18 0.33 0.01 37.33 0.23 0.50 0.46 p = 9.2× 10−28
(f) 0.79 0.45 1.74 0.31 0.14 2.31 0.06 0.31 0.20 p = 3× 10−38
Table 3: Selected ranking performance measures for P-GLAW and GG for the 6 scenarios described in
Table 1. ROC power, fpr = 0.05: proportion of 500 MC simulations with rk1 ≤ 28 corresponding to a fpr
of 0.05. median p100: median of p100 distribution across 500 MC simulations. Proportion with p100 = 0:
proportion of 500 MC simulations with no causal pathway in the top 100 ranks. KS 2 sample test: two-
sample Kolmogorov-Smirnov test of the hypothesis that the P-GLAW and GG p100 population cdfs are
the same.
Beginning with the ROC curves illustrating the rk1 ranking measure (Fig. 7 and first 3 columns
of Table 3), GG consistently demonstrates increased power and specificity across all of the top 100
ranks illustrated. In addition, the relative gain in power for P-GLAW is greater at the smallest
effect size for each equivalent scenario, (a) vs. (d), (b) vs. (e), and (c) vs. (f). At the smaller effect
size, where causal SNPs are distributed randomly within causal pathways, power increases where
the number of causal SNPs is fewer ((d) vs. (e)). Finally, maximum power is achieved for both
methods where causal SNPs are located within a single gene ((c) and (f)).
Turning to the distributions of the p100 ranking measure (Fig. 8, and columns 4 to 9 in Table 3),
P-GLAW again outperforms GG across all scenarios. For example, the null hypothesis that the
two population cdfs are equal is rejected at the α = 0.05 level (Table 3, final column), as is the
null hypothesis that the two sample medians are the same (Fig. 8), except for scenario (a) where
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Figure 6: Comparison of ranking performance: adaptive weighting scheme (section 2.3) vs. standard
pathway size weighting (13). S = 10; δk = 0.005; SNPs randomly distributed across Gφ. (a) ROC curves
illustrating power to identify at least one causal pathway in the top 100. Power is average across 500
simulations. (b) Distribution of ranking power, p100, across 500 simulations. This is the proportion
|C|∗100|/|C| of causal pathways in C that are ranked in the top 100 pathways. Notches indicate 95%
confidence intervals for the true median. (c) Distribution of the power-adjusted, normalised, weighted
ranking score, R, across 500 simulations. The final ‘50+’ column includes simulations for which no causal
pathway was ranked in the top 100, i.e. C∗100 = ∅;R = 100.
median p100 is not significantly different for the two methods. Excluding scenario (a) where both
methods perform relatively well, P-GLAW median p100 is consistent across each scenario, and is
maintained from the larger to the smaller effect size. This is in marked contrast to GG, where
this measure shows a large decrease at the smaller effect size, although the decrease is less marked
when causal SNPs are located within a single gene. A similar pattern persists for both P-GLAW
and GG if we consider the proportion of simulations with p100 = 0, i.e. where no causal pathways
are found in the top 100 ranks, except for P-GLAW in the case where causal SNPs are located in
a single gene, where this measure is particularly low.
The final series of plots (Fig. 9), illustrate the distributions of R across all scenarios. These
distributions once again follow the trends in ranking performance highlighted above, but they offer
a more nuanced view, in the sense that while this measure takes power into account, it is also
sensitive to the actual causal pathway rankings. Here we see that P-GLAW tends to rank causal
pathways higher than GG, since all P-GLAW distributions are skewed towards lower R values,
indicating that causal pathways tend to be ranked higher. This is borne out if we focus on the
proportion of simulations with R < 10 (Table 4, first 3 columns), which also illustrates how pro-
portionate gains in ranking performance for P-GLAW over GG are largest for the smallest effect
size ((a)-(c) vs. (d)-(f)). This table also gives results for the proportion of simulations demon-
strating near optimal ranking of causal pathways (R < 3), although the very small frequencies
suggest that little can be inferred from these.
scenario R < 10 R < 3
P-GLAW GG ratio P-GLAW GG ratio
(a) 0.68 0.46 1.47 0.13 0.09 1.38
(b) 0.50 0.24 2.11 0.03 0.03 0.93
(c) 0.55 0.33 1.68 0.01 0.07 0.18
(d) 0.44 0.20 2.22 0.03 0.02 2.00
(e) 0.46 0.20 2.33 0.02 0.03 0.69
(f) 0.45 0.23 1.96 0.01 0.04 0.30
Table 4: Proportion of 500 simulations with R < 10 and R < 3 for the 6 scenarios described in Table 1.
5 Discussion
We have developed a penalised regression-based strategy (P-GLAW) that exploits functional struc-
ture within genotypes to identify biological pathways associated with a continuous trait. We use
the group lasso, with all mapped SNPs and pathways in a single regression model, and use a novel
combination of methods including a bias-adjusted group weighting scheme and bootstrap sam-
pling, together with a number of speed ups designed to make the analysis of large scale datasets
computationally feasible. An important feature of our method is the need to accommodate the
presence of overlapping pathways. On the assumption that causal SNPs are enriched within a
biological pathway, we find in a simulation study that our proposed method shows relative gains
in both power and specificity across a range of scenarios, compared with an alternative pathways
method (GG), based on univariate SNP statistics, that we use as a benchmark. We believe this is
the first such study evaluating GL performance using real SNP and pathway data across a range
of realistic scenarios.
One key motivation for a pathways-based approach is the desire to harness the joint effects of
those SNPs or genes with relatively small effect size, that typically fail to achieve genome-wide
significance in GWAS (Baranzini et al., 2009). We hypothesise that the advantages inherent in
a multivariate approach to modelling SNP effects will increase power to detect these, and in our
simulation study we therefore focus on scenarios with causal SNPs that exhibit effect sizes at or
below the limits of those found in recent GWAS. To evaluate the performance of each method
considered here, we devise three separate ranking metrics, each of which measures a different
aspect of ranking performance.
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Figure 7: ROC curves illustrating proportion of simulations with rk1 ≤ z, for ranks z = 1, 2, . . . , 100.
Power is average across 500 simulations. False positive rate = (z − 1)/L. Scenarios corresponding to the
higher SNP effect size (δk = 0.005) are presented in the left-hand column, with the equivalent scenarios
at the lower effect size (δk = 0.001) on the right.
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Figure 8: Box plots of distribution of ranking power, p100, across 500 simulations. This is the proportion
|C|∗100/|C| of causal pathways in C that are ranked in the top 100 pathways. Notches indicate 95% confidence
intervals for the true median.
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Figure 9: Distribution of the power-adjusted, normalised, weighted ranking score, R, across 500 simula-
tions. The final ‘50+’ column includes simulations for which no causal pathway was ranked in the top
100, i.e. C∗100 = ∅;R = 100.
One factor affecting power is the ‘genetic architecture’ of the disease in question, that is the
number and distribution of SNP effects across causal pathways (Wang et al., 2010). For example,
causal SNPs may be distributed across many genes in a pathway, or restricted to a single gene.
Since PGAS methods vary in the way that they combine the effects of individual SNPs, the specific
genetic architecture is expected to impact power for different methods in different ways (Wang
et al., 2009b; Holmans et al., 2009). GG uses genes scores corresponding to the most significant
SNP associated with a gene to establish pathway significance. This has the advantage of reducing
redundant information arising from SNPs in LD with a causal SNP within a single gene, but may
lead to reduced power where causal variants reside in distinct LD blocks within a gene (Wang
et al., 2007). An important, related factor that we find has received little attention is the issue of
overlapping pathways, and the consequent effect on PGAS performance. The precise distribution
of causal SNPs with respect to genes that overlap multiple pathways will affect the number of
pathways that are considered to be ‘causal’, and we expect this to affect ranking performance for
different methods in different ways. To explore these issues, we investigate a variety of different
genetic architectures, in which we vary both the number and distribution of causal SNPs with
respect to pathways and genes.
In general, we find that P-GLAW performs well across the range of causal SNP distributions and
effect sizes considered. Additionally, our method is able to consistently outperform the benchmark
(GG). GG performance at the smaller effect size is particularly weak, so that P-GLAW shows the
largest gains in relative performance here.
An insight into some of those factors affecting ranking performance is afforded by considering
some of the ranking measures in more detail. Starting with the highest ranking causal pathway
measure (rk1), as expected we find that this decreases for each scenario at the smaller effect size.
However, at the smaller effect size this measure is observed to increase for both methods as the
number of causal SNPs is decreased, markedly so when the reduced number of causal SNPs are
concentrated in a single gene. Since the effect size for each causal SNP is held constant, this
seems counterintuitive, since the pathway ‘signal’ is reduced when there are fewer causal SNPs. In
addition, for the reasons described above, for GG this signal may be further reduced where causal
SNPs reside within a single gene. The explanation is likely to be that the effective number of causal
pathways tends to increase as the number of causal SNPs is reduced, increasing the probability
that a single causal pathway is ranked high. The number of causal pathways is even larger when
causal SNPs are concentrated in a single gene (see Fig. 4). Where the pathway signal is highest
(scenario (a)), both methods tend to rank a high proportion of causal pathways in the top 100
(high p100), although the proportion of MC simulations in which GG fails to rank any causal
pathways (that is the proportion of simulations with p100 = 0) is relatively high. On this measure
of ranking power, GG performs relatively poorly across all other scenarios, particularly at the
smaller effect size. Interestingly, P-GLAW is relatively insensitive to variation in the number and
distribution of SNPs within causal pathways, as might be expected from the smoothing properties
of the GL `2 penalty, which ensures that all SNPs within a selected pathway are retained in the
model (Zhou et al., 2010).
The need to account for factors such as variation in LD, gene and pathway size is a feature
common to all PGAS methods. A range of approaches, often used in combination, have been
proposed to correct for these biasing factors, including the use of gene scores that summarise SNP
statistics (Holmans et al., 2009), and permutation of phenotypes (Wang et al., 2009b). Dimen-
sionality reduction techniques have also been advocated for the control of redundant information
(Chen et al., 2010; Zhu and Li, 2011; Ballard et al., 2010). For P-GLAW, we propose a method that
adjusts the distribution of pathway weights according to the observed bias in pathway selection
frequencies across multiple MC simulations under the null. We find in a simulation study that our
proposed bias correction method does substantially increase power and specificity, indicating that
pathway selection bias is decreased. One potential disadvantage of our approach is that it takes
no account of variation in biasing factors within a pathway. It would be interesting to compare
the relative merits of our approach against alternative bias-reduction methods, for example the
use of within-pathway dimensionality reduction. However, we consider the retention of all SNPs
in the regression model to be a potentially attractive feature of our approach, as it affords the
possibility of the simultaneous identification of causal SNPs driving pathway selection, and we are
currently pursuing this as an extension to the present model.
In situations where predictors, or groups of predictors are correlated, both the lasso and group
lasso can demonstrate problems with consistency, that is they are unable to constently identify
the true set of causal predictors or groups (Zhao and Yu, 2006; Bach, 2008; Chatterjee and Lahiri,
2011). Despite this, we have demonstrated that in a finite sample, our bootstrap sampling approach
performs well, and this has been borne out elsewhere (Meinshausen and Bu¨hlmann, 2010). We
are however pursuing alternative methods for the ranking of pathways, using different ranking
strategies.
We pay considerable attention to the need to develop fast algorithms for solving the GL,
a problem that is particularly acute when using regression models with GWAS data. Using a
combination of techniques, we establish a GL estimation algorithm that can quickly solve the GL
using whole genome data. However, the very large number of simulations and scenarios considered
in our simulation study, and the relatively slow performance of the benchmark method mean that
we restrict the analysis to mapped SNPs from a single chromosome.3
We note that phenotypes in our simulation study are generated under an additive linear model.
The assumption of additive linear SNP effects is built into both the P-GLAW and GG models, in
the former through the SNP allele codings in the genotype design matrix, and in the latter through
the particular model used to generate the univariate SNP scores, although for both methods
alternative models can easily be accommodated.
In our simulation study we account for variation in the size and distribution of causal SNP
minor allele frequencies through the use of MC simulations, but we expect that such variation is
likely to impact model performance, and this is something that warrants further exploration.
As with all PGAS methods, we note that results are dependent on the choice of pathways
database, and will inevitably reflect biases due for example to the increased number of annotations
for genes implicated in particular disease etiologies (Elbers et al., 2009; Cantor et al., 2010).
Results are also subject to bias resulting from SNP to gene mapping strategies. For example, SNP
to gene mapping distances will affect the number of unmapped SNPs falling within gene ‘deserts’
(Eleftherohorinou et al., 2009), SNPs will map to relatively large numbers of genes in gene rich
areas of the genome, and the mapping of a SNP to its closest gene may obscure a true functional
relationships with a more distant gene (Wang et al., 2009b).
Finally, we note that our method can be easily adapted to accommodate other ways of grouping
SNP data, for exampling using protein interaction networks (Wu et al., 2010), or GO and other
ontologies (Jensen and Bork, 2010).
Appendix Line search over λ
We wish to tune λ so as to select a minimum M pathways at each subsample. To do this we
perform a line search over λ. This procedure is described in box 3.
Box 3 Line search procedure for tuning λ to select M ≥Mmin pathways
1. Set λmax = minλ : ||XTl y||2 ≤ λwl (from (12)) and α = 0.8†
2. Let λ = αλmax
3. Form the active set, A = {m ∈ G : ||XTmy||2 ≤ λwm}
4. Let M = |A|. If M < Mmin skip to step 6.‡
5. Solve the GL estimation at λ using the active set A, as described in box 2 (starting at box
2, step 2.)
3Python code for mapping SNPs to pathways, and for analysing SNP data using PGLAW is available on request.
Let the solution be βˆ, with final active set A
S(λ) = {l ∈ G : ||βˆl|| > 0} (the set of selected pathways)
M = |S(λ)| (the number of selected pathways)
6. if M ≥Mmin
βˆ is the full solution
STOP
else
λmax = λ (need to decrease λ)
end
7. Go to step 2.
† The value of α is chosen for computational convenience. A value close to 1 ensures that λ values stay
close to 1, so that as few pathways are selected by the model as possible, thus speeding up the estimation.
However, a value too close to 1 means that the decrease in λ at each iteration is small, meaning that many
iterations may have to be performed before M reaches the desired range.
‡ This step is introduced for computational efficiency, since if |A| < Mmin there is no prospect of selecting
enough groups
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